Hence, HN1L/AP-2γ/PLK1/CCND1-SLUG signaling axis drives ESCC progression and chemotherapy resistance, suggesting that blocking PLK1 may attenuate the oncogenic role of HN1L. The gene discussed is PLK1; the disease is esophageal squamous cell carcinoma.